Thermo Buys Cohesive, Raises ’07 Revs
Thermo Fisher Scientific said last week it has acquired Cohesive Technologies, a manufacturer of sample extraction and liquid chromatography products. The company did not disclose terms of the acquisition.
In a statement, Thermo Fisher said the deal adds in-line sample preparation capabilities that coupled with mass spectrometry technology, “will significantly improve sample throughput and increase detection limits during LC/MS/MS analysis,” the company said.
Cohesive has annual revenues of approximately $15 million.
Thermo Fisher also raised its revenue guidance for 2007 to $9.4 billion to $9.5 billion from an earlier estimate of $9.2 billion to $9.3 billion.
Call for Research on Protein Biomarkers for Infection-Linked Cancer
The National Institutes of Health is seeking researchers to conduct work on protein biomarkers for cancer linked to infectious diseases. The long-term goal is for the development and use of such biomarkers to detect, assess, and treat such cancers.
Information about grants to fund such research and the application form for the grants are available here.
According to the NIH, about 15 percent of all cancer cases are caused by infectious agents such as viruses, bacteria and other pathogens. Such agents are ubiquitous though only a small percentage of individual infected develop cancer.
“The objective of this program announcement is to foster research to identify those who are at increased risk of developing cancer among infected individuals and to detect early stage cancers in this population,” the NIH said.
Bruker to Offer 10.4M Shares
Bruker BioSciences said last week it has filed with the US Securities and Exchange Commission to offer a total of 10.4 million shares of its common stock. Of that, the company is offering 2.2 million shares with the balance being offered by four members of the Laukien family. Frank Laukien, president and CEO of Bruker, is not one of the members offering the shares.
The company and its selling shareholders have granted the underwriters a 30-day option to purchase an aggregate of up to 1.56 million shares to cover any over-allotments. Bear, Stearns & Co. and UBS Securities are acting as joint bookrunning managers for the offering, Bruker said in a statement.
CombiMatrix Cancels Agreement with Cornell Capital Partners
CombiMatrix said this week it is canceling its standby equity distribution agreement with Cornell Capital Partners. CombiMatrix provided no comment or reason for the cancellation.
In June, CombiMatrix said it would sell registered shares of its common stock to Cornell at a 2.5 percent discount as part of a standby equity distribution agreement up to $50 million.
Digilab IDs Candidate Lung Cancer Biomarkers, Abbot Exercises Evaluation Right
Abbott Molecular has exercised its right to evaluate option candidate markers from Digilab after that company announced this week it has identified candidate biomarkers for lung cancer. Digilab said the discovery was made using the company’s proprietary Peptidomics Differential Peptide Display platform.
Abbott has the right to acquire an exclusive royalty-bearing license from Digilab to such candidate markers, Digilab said in a statement.
Pressure BioSciences sell PCT system to CDC
Pressure BioSciences said this week it has sold a Pressure Cycling Technology sample preparation system to the Centers for Disease Control and Prevention.
Scientists at the CDC expect to use the system for the extraction of proteins from influenza virus, bacterial agents, and tissues from laboratory animals that have been exposed to bioterrorism agents such as anthrax, Pressure BioSciences said in a statement.